Murray J. Towle

1.9k total citations
24 papers, 1.1k citations indexed

About

Murray J. Towle is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Murray J. Towle has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Oncology and 6 papers in Organic Chemistry. Recurrent topics in Murray J. Towle's work include Cancer Treatment and Pharmacology (9 papers), HER2/EGFR in Cancer Research (5 papers) and Microbial Natural Products and Biosynthesis (4 papers). Murray J. Towle is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), HER2/EGFR in Cancer Research (5 papers) and Microbial Natural Products and Biosynthesis (4 papers). Murray J. Towle collaborates with scholars based in United States, Japan and Italy. Murray J. Towle's co-authors include Bruce A. Littlefield, Melvin J. Yu, Yoshito Kishi, Galina Kuznetsov, Hongsheng Cheng, Karen TenDyke, Kenneth A. Ault, Diana Liu, Takanori Kawamura and Boris M. Seletsky and has published in prestigious journals such as New England Journal of Medicine, Nucleic Acids Research and The Journal of Experimental Medicine.

In The Last Decade

Murray J. Towle

24 papers receiving 1.1k citations

Peers

Murray J. Towle
Nerea Allende-Vega France
Ikuko Suzuki‐Takahashi Japan
Jiaquan Wu United States
Jessica Hauschild Germany
Caroline B. Ho United States
Yoshiharu Mizui Japan
Chih‐Jian Lih United States
Rudi Bao United States
Irma M. Grossi United States
Christoph Geisen Germany
Nerea Allende-Vega France
Murray J. Towle
Citations per year, relative to Murray J. Towle Murray J. Towle (= 1×) peers Nerea Allende-Vega

Countries citing papers authored by Murray J. Towle

Since Specialization
Citations

This map shows the geographic impact of Murray J. Towle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murray J. Towle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murray J. Towle more than expected).

Fields of papers citing papers by Murray J. Towle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murray J. Towle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murray J. Towle. The network helps show where Murray J. Towle may publish in the future.

Co-authorship network of co-authors of Murray J. Towle

This figure shows the co-authorship network connecting the top 25 collaborators of Murray J. Towle. A scholar is included among the top collaborators of Murray J. Towle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murray J. Towle. Murray J. Towle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Asano, Makoto, Junji Matsui, Murray J. Towle, et al.. (2018). Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms. Anticancer Research. 38(6). 3375–3385. 27 indexed citations
2.
3.
Towle, Murray J., K. Nomoto, Makoto Asano, et al.. (2012). Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.. PubMed. 32(5). 1611–9. 38 indexed citations
4.
Wozniak, Krystyna M., K. Nomoto, Rena G. Lapidus, et al.. (2011). Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice. Cancer Research. 71(11). 3952–3962. 75 indexed citations
5.
Narayan, Sridhar, Hongsheng Cheng, Hong Du, et al.. (2011). Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo. Bioorganic & Medicinal Chemistry Letters. 21(6). 1634–1638. 12 indexed citations
6.
Narayan, Sridhar, Hongsheng Cheng, Hong Du, et al.. (2011). Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility. Bioorganic & Medicinal Chemistry Letters. 21(6). 1630–1633. 16 indexed citations
7.
Narayan, Sridhar, Hongsheng Cheng, Hong Du, et al.. (2011). Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model. Bioorganic & Medicinal Chemistry Letters. 21(6). 1639–1643. 16 indexed citations
8.
Towle, Murray J., Kathleen A. Salvato, Bruce F. Wels, et al.. (2010). Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions. Cancer Research. 71(2). 496–505. 111 indexed citations
9.
Wozniak, Krystyna M., Rena G. Lapidus, Ying Wu, et al.. (2010). Abstract 4438: Comparison of neuropathy-inducing effects of eribulin versus paclitaxel in mice. Cancer Research. 70(8_Supplement). 4438–4438. 2 indexed citations
10.
Kuznetsov, Galina, Qunli Xu, Karen TenDyke, et al.. (2009). Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Molecular Cancer Therapeutics. 8(5). 1250–1260. 85 indexed citations
11.
Wu, Jiayi, K. Nomoto, John Wang, et al.. (2009). Abstract #3687: In vivo anticancer activity of E6201, a novel MEK1 inhibitor, against BRAF-mutated human cancer xenografts. Cancer Research. 69. 3687–3687. 3 indexed citations
12.
Liu, Junke, Murray J. Towle, Hongsheng Cheng, et al.. (2007). In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent.. PubMed. 27(3B). 1509–18. 63 indexed citations
13.
Rudolph‐Owen, Laura A., Kathleen A. Salvato, Hongsheng Cheng, et al.. (2004). A 96-well plate cell-based assay to quantify undesired cytotoxic effects against quiescent non-dividing cells. Cancer Research. 64. 264–265. 3 indexed citations
14.
Seletsky, Boris M., Yuan Wang, Lynn D. Hawkins, et al.. (2004). Structurally simplified macrolactone analogues of halichondrin B. Bioorganic & Medicinal Chemistry Letters. 14(22). 5547–5550. 56 indexed citations
15.
Zheng, Wanjun, Boris M. Seletsky, Monica H. Palme, et al.. (2004). Macrocyclic ketone analogues of halichondrin B. Bioorganic & Medicinal Chemistry Letters. 14(22). 5551–5554. 114 indexed citations
16.
17.
Bridges, Alexander J., Arthur Lee, C. Schwartz, Murray J. Towle, & Bruce A. Littlefield. (1993). The synthesis of three 4-substitutedbenzo[b]thiophene-2-carboxamidines as potent and selective inhibitors of urokinase. Bioorganic & Medicinal Chemistry. 1(6). 403–410. 22 indexed citations
18.
Strair, Roger, Murray J. Towle, & Brian R. Smith. (1990). Retroviral mediated gene transfer into bone marrow progenitor cells: use of beta-galactosidase as a selectable marker. Nucleic Acids Research. 18(16). 4759–4762. 24 indexed citations
19.
Strair, Roger, Murray J. Towle, & Brian R. Smith. (1988). Recombinant retroviruses encoding cell surface antigens as selectable markers. Journal of Virology. 62(12). 4756–4759. 17 indexed citations
20.
Ault, Kenneth A. & Murray J. Towle. (1981). Human B lymphocyte subsets. I. IgG-bearing B cell response to pokeweed mitogen.. The Journal of Experimental Medicine. 153(2). 339–351. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nerea Allende-Vega Breakdown of academic impact, for papers by Ikuko Suzuki‐Takahashi Breakdown of academic impact, for papers by Jiaquan Wu Breakdown of academic impact, for papers by Jessica Hauschild Breakdown of academic impact, for papers by Caroline B. Ho Breakdown of academic impact, for papers by Yoshiharu Mizui Breakdown of academic impact, for papers by Chih‐Jian Lih Breakdown of academic impact, for papers by Rudi Bao Breakdown of academic impact, for papers by Irma M. Grossi Breakdown of academic impact, for papers by Christoph Geisen
Rankless by CCL
2026